A biosecurity response to Aedes albopictus (Diptera: Culicidae) in Auckland, New Zealand.

J Med Entomol

Plant Health and Environment Laboratory, Ministry of Agriculture and Forestry Biosecurity New Zealand, Box 14018, Christchurch Airport 8544, New Zealand.

Published: July 2010

A biosecurity response was triggered by the detection of Aedes albopictus (Skuse) (Diptera: Culicidae) at the Port of Auckland, New Zealand. Ae. albopictus does not occur in New Zealand and is the most significant mosquito threat to this country. The possibility that a founding population had established, resulted in a large-scale biosecurity surveillance and control program. The response was initiated in early March 2007 and completed by mid-May 2007. No further exotic mosquitoes were detected. The response surveillance program consisted of larval habitat surveys and high density ovi- and light trapping. It was coordinated with a habitat modification and S-methoprene treatment control program. The response policies were guided by analysis of surveillance and quality assurance data, population modeling, and trace-back activities. Mosquito habitat and activity close to port were both more abundant than expected, particularly in storm water drain sumps. Sumps are difficult to treat, and during the response some modification was required to the surveillance program and the control regime. We were assured of the absence or eradication of any Ae. albopictus population, as a result of nil detection from surveillance, backed up by four overlapping rounds of insecticide treatment of habitat. This work highlights the importance of port surveillance and may serve as a guide for responses for future urban mosquito incursions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027260PMC
http://dx.doi.org/10.1603/me09111DOI Listing

Publication Analysis

Top Keywords

biosecurity response
8
aedes albopictus
8
diptera culicidae
8
auckland zealand
8
control program
8
program response
8
surveillance program
8
surveillance
6
response
5
response aedes
4

Similar Publications

Enhancing vaccine half-life as a novel strategy for improving immune response durability of subunit vaccines.

PLoS Pathog

January 2025

Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS) and Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.

Vaccines are widely regarded as one of the most effective strategies for combating infectious diseases. However, significant challenges remain, such as insufficient antibody levels, limited protection against rapidly evolving variants, and poor immune durability, particularly in subunit vaccines, likely due to their short in vivo exposure. Recent advances in extending the half-life of protein therapeutics have shown promise in improving drug efficacy, yet whether increasing in vivo persistence can enhance the efficacy of subunit vaccines remains underexplored.

View Article and Find Full Text PDF

Avian Reovirus: From Molecular Biology to Pathogenesis and Control.

Viruses

December 2024

Southeast Poultry Research Laboratory, U.S. National Poultry Research Center, United States Department of Agriculture-Agricultural Research Service (USDA-ARS), Athens, GA 30605, USA.

Avian reoviruses (ARVs) represent a significant economic burden on the poultry industry due to their widespread prevalence and potential pathogenicity. These viruses, capable of infecting a diverse range of avian species, can lead to a variety of clinical manifestations, most notably tenosynovitis/arthritis. While many ARV strains are asymptomatic, pathogenic variants can cause severe inflammation and tissue damage in organs such as the tendons, heart, and liver.

View Article and Find Full Text PDF

Multi-Component Protein Vaccine Induces a Strong and Long-Term Immune Response Against Monkeypox Virus.

Vaccines (Basel)

December 2024

State Key Laboratory of Pathogens and Biosecurity, Academy of Military Medical Sciences, Beijing 100071, China.

Background/objectives: Since 2022, outbreaks of monkeypox have raised widespread concern and have been declared a public health emergency of international concern by the World Health Organization. There is an urgent need to develop a safe and effective vaccine against the monkeypox virus (MPXV). Recombinant protein vaccines play a significant role in the prevention of infectious diseases due to their high safety and efficacy.

View Article and Find Full Text PDF

Laboratory mice are instrumental for preclinical research but there are serious concerns that the use of a clean standardized environment for specific-pathogen-free (SPF) mice results in poor bench-to-bedside translation due to their immature immune system. The aim of the present study was to test the importance of the gut microbiota in wild vs. SPF mice for evaluating host immune responses in a house-dust-mite-induced allergic airway inflammation model without the influence of pathogens.

View Article and Find Full Text PDF

Regulation (EU) 2016/429 introduces comprehensive guidelines for managing transmissible animal diseases, including zoonoses. The subsequent Commission Implementing Regulation 2018/1882 categorizes these diseases into five groups, each with specific responses, ranging from mandatory eradication to optional eradication or surveillance. Key regulatory priorities include enhanced animal traceability, biosecurity, wildlife pathogen control, sustainable farming practices, and minimizing the impact of diseases on public health, animal health, and the environment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!